Navigation Links
drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
Date:2/6/2008

order were $75 for the quarter and year. Average

net sales per order increased to $59 for OTC, grew 10% to $102 for

vision, and were $107 for local pick-up pharmacy and $165 for

mail-order pharmacy. For the year, average net sales per order

increased to $57 for OTC, grew 10% to $99 for vision, and were $106 for

local pick-up pharmacy and $159 for mail-order pharmacy.

-- Net sales from repeat customers [2] represented 80% of net sales for

the quarter and 82% of net sales for the year.

Key Customer Milestones:

-- New customers grew to 398,000.

-- We have now served nearly 10 million customers since inception.

-- The number of active customers [3] was 2.5 million.

1. Core OTC net sales is a non-GAAP financial measure that excludes from

OTC net sales the company's Custom Nutrition Services ("CNS") net

sales. CNS sales are generated by sales of customized vitamins through

the company's CNS subsidiary. Prior to December 31, 2005, all CNS

sales were recognized on a gross basis, net of promotional discounts,

cancellations, rebates and returns allowances. Under the terms of the

company's December 31, 2005 fulfillment agreement with Weil Lifestyle,

LLC (Weil), the company recognizes on a net basis the revenue

associated with the fulfillment of customized vitamins sold through its

fulfillment agreement with Weil. A reconciliation of OTC net sales to

core OTC net sales is included in the financial data accompanying this

press release.

2. Net sales from repeat customers exclude Weil-related CNS net sales and

reflect only the activity of customers making purchases through the Web

sites of drugstore.com and its subsidiaries.

3. Active customer base reflects those customers who have purchased at

least once within the last 12 months. Both the active cu
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
2. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
3. drugstore.com and Revolution Health Group Announce Breakthrough Deal
4. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
5. Joint Commission International Achieves Accreditation from ISQua
6. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
7. Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. LMS integrated obstetrics solution achieves general availability
11. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ire-FirstCall/ -- SpectraScience, Inc.,(OTC Bulle... company, today,announced that it has been awarde... for Tissue Diagnosis. , Jim Hitchin, SpectraSc...to,the Company,s optical biopsy technology becaus...urveillance, characterization, diagnosis and treat...
(Date:12/1/2008)... higher risk for SIDS and this may be why, researc...ews) -- Premature infants often have lower-than-no... six months of life and may be one reason these in...me (SIDS), Australian researchers suggest. , On...n blood pressure during sleep, from which the infa...
(Date:12/1/2008)...RNewswire-USNewswire/ -- As part of the Dec. 1 o...ealth Everette James today urged Pennsylvanians to...e also highlighted ongoing efforts to educate the ..., , "Our message is clear: regardless of yo...ing tested for HIV is the only sure way to know yo...
(Date:12/1/2008)...hers used a new imaging technique to take high qua...cular inflammation in mice, and the technology cou...s of the eye that may cause blindness. , The stu...immune Uveoretinitis Using Topical Endoscopic Fund... Correlation," was published in the Association fo...
Breaking Medicine News(10 mins):Health News:SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis 2Health News:Preemies' Low Blood Pressure Linked to SIDS 2Health News:Preemies' Low Blood Pressure Linked to SIDS 3Health News:PA Department of Health Recognizes 20th Anniversary of World AIDS Day; Urges HIV Testing 2Health News:New technique captures high-res images of full retina 2
... study has dismissed any association between consu... study examined the association between total calc...t. Diet and calcium supplements formed the main so... 19,000 men between the age of 40 and 75 years wer...
...n is a sleeping pill. But lately it is has been li... drivers. Wisconsin officials identified Ambien in...cials say that there are signs that Ambien-related... Sanofi-Aventis said that the drug is safe when ta...
...ne with the International Women’s Day celebrations... the Chennai-based Apollo hospitals. Ms. J. Jayala...women health care center on Wednesday. // The hea...all health problems of the women folk including su...
... University of Toronto study by Professor David Je...holesterol-lowering foods as soy protein, almonds,... these may reduce cholesterol levels more effectiv... study is published in American Journal of Clinica...
Other Medicine News:Health News:Ambien Plus Alcohol Has A Bad Influence on the Drivers 2Health News:Try a consortia of cholesterol-lowering foods for best results 2
(Date:11/25/2008)... 25 Poniard,Pharmaceuti...company focused on,innovative oncology therapies,...gic alternatives for its preclinical research prog...esources on the clinical development of picoplatin...initial commercialization of,picoplatin in the tr...
(Date:11/24/2008)..., Nov. 24 Takeda Pharmaceutical Co...eda Global Research & Development Center, Inc....y Committee of the U.S. Food and Drug Administrati...at for the treatment of hyperuricemia in patients...proval, with one panel member abstaining. The vote...
(Date:11/24/2008)...leadership and long-term commitment to hepatitis r...wswire-FirstCall/ -- Schering-Plough Corporation (...boceprevir, its lead investigational oral hepatiti...lopment. The company believes boceprevir has the ... protease inhibitor for treating chronic hepatitis...
(Date:11/24/2008)...wswire-FirstCall/ -- GeneThera, Inc.,(Pink Sheets...its Real Time,PCR test for Johne,s disease throug...Thera is set to begin offering its Johne,s disease...ording to GeneThera Chairman, Dr. Tony Milici MD,...R test for Johne,s disease,called HerdGuard(TM) ...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Lifetime Television Launches Third Annual Dont Skip a Beat Multi Platform Heart Health Awareness Initiative 10786 1Lifetime Television Launches Third Annual Dont Skip a Beat Multi Platform Heart Health Awareness Initiative 10786 2Lifetime Television Launches Third Annual Dont Skip a Beat Multi Platform Heart Health Awareness Initiative 10786 3Election 2008 3A Sleep deprivation a tough opponent for presidential candidates 10781 1Election 2008 3A Sleep deprivation a tough opponent for presidential candidates 10781 2MDS Inc Files Restated 2007 Quarterly Reports Under US GAAP 10779 1On Heels of SCHIP Veto President Advocates Eliminating Federal Funding for Training Childrens Doctors 10775 1On Heels of SCHIP Veto President Advocates Eliminating Federal Funding for Training Childrens Doctors 10775 2
...WIRE)--Apr 18, 2007 - Nymox,Pharmaceutical Corpora...a new 42 month follow-up study of NX-1207 for beni...d symptomatic,progress of U.S. patients involved i... 2003. Individuals in the study were assessed,for ...urability of,efficacy. Patients in the study were ...
...ion for Cancer Research Annual,Meeting, SAN DIEGO,...,Pharmaceuticals, Inc. , a biopharmaceutical resea...zing proprietary product,candidates for the treatm...nced positive results from preclinical studies usi... (CoFactor(R)) at the,American Association for Can...
Other Medicine Technology:Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 3Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 4
... of cerclage wiring, the Cable-Ready Cable Grip1 S...e minimizing invasion of the wound site. The syste... technique. , ,The Cable-Ready Cable Grip system ...y involving: Olecranon Fractures, Femur Fractures,...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery.
The Taperloc femoral component is a collarless flat wedge-shaped implant that provides excellent durability and stability in a design that is relatively simple and predictable to implant. The incorpo
Build your Basic Small Joint Set from the suggested instruments or select other insruments for the set.
Medicine Products: